Emission computed tomography

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Medical physics, Medical imaging, Neuroimaging, Medical specialties, Image processing, Nuclear medicine, Positron emission tomography, Tomography, Single-photon emission computed tomography, Emission computed tomography, Rigaku

Through this acquisition, Rigaku will expand its life sciences modality business globally by combining MILabs' multi-modality businesses, including PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), Optical Imaging, and CT (Computed Tomography) equipment for animals, with Rigaku's original X-ray imaging business for animals.

Key Points: 
  • Through this acquisition, Rigaku will expand its life sciences modality business globally by combining MILabs' multi-modality businesses, including PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), Optical Imaging, and CT (Computed Tomography) equipment for animals, with Rigaku's original X-ray imaging business for animals.
  • Through this acquisition, Rigaku aims to strengthen its pre-clinical imaging business within the life sciences field by incorporating MILabs' radiation imaging and optical imaging technologies, a new initiative for Rigaku, while simultaneously building its existing X-ray imaging business.
  • Rigaku believes that pre-clinical imaging will become increasingly important in the life sciences field.
  • Rigaku will actively enter the life science market and aim to develop this field as one of its core businesses by 2025.

Global Single Photon Emission Computed Tomography (SPECT) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Technology, Medical devices, Other Technology, Cardiology, Radiology, Health, Pharmaceutical, General Health, Oncology, Neuroimaging, Medicine, Clinical medicine, Branches of biology, Radiobiology, Medical imaging, Emission computed tomography, Tomography, Single-photon, Advanced Cyclotron Systems, Draft:MILabs

The "Single Photon Emission Computed Tomography (SPECT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single Photon Emission Computed Tomography (SPECT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 6.8% over the period 2020-2027.
  • This segment currently accounts for a 43.8% share of the global Single Photon Emission Computed Tomography (SPECT) market.
  • The U.S. Accounts for Over 36.1% of Global Market Size in 2020, While China is Forecast to Grow at a 9.4% CAGR for the Period of 2020-2027
    The Single Photon Emission Computed Tomography (SPECT) market in the U.S. is estimated at US$608.4 Million in the year 2020.

The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Medical physics, Medicine, Neuroimaging, Medical specialties, Radiobiology, Radiation therapy, Glutamate carboxypeptidase II, Peptidase, Single-photon emission computed tomography, Emission computed tomography, Positron emission tomography

The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost-effective and viable alternative.

Key Points: 
  • The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost-effective and viable alternative.
  • \xe2\x80\x9cHowever, millions of men do not have access to PET imaging.
  • For this reason, it is our aspiration to develop a powerful, affordable, and widely available alternative imaging tool by using iPSMA SPECT technology.\xe2\x80\x9d\n\xe2\x80\x9cIntroducing PSMA has been difficult and exciting for the team at Ibadan.
  • When I think of the opportunities for prostate cancer research and management without PET, I am motivated to get past the challenges.

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals

Retrieved on: 
Wednesday, March 3, 2021
Medical Supplies, Cardiology, Biotechnology, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Medicine, Medicinal radiochemistry, Nuclear medicine, Physical sciences, Radiobiology, Radiopharmaceuticals, Medical physics, Radiology, Single-photon emission computed tomography, Medical imaging, Radiopharmacology, Emission computed tomography

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business.
  • View the full release here: https://www.businesswire.com/news/home/20210303005055/en/
    Dave Wilson, RPh., BCNP, VP Advanced Radiopharmaceutical and Therapeutic Technologies, NorthStar Medical Radioisotopes (Photo: Business Wire)
    In conjunction with other organizational changes, NorthStar has appointed Dave Wilson, RPh., BCNP, as Vice President, Advanced Radiopharmaceutical and Therapeutic Technologies.
  • NorthStar is also actively developing and growing its strategic portfolio of specialized SPECT radiopharmaceuticals to meet increasing clinical needs for SPECT imaging, driven by scientific advancements in cardiology and oncology.
  • NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that develops, produces and manufactures reliable and environmentally-friendly diagnostic and therapeutic radiopharmaceuticals.

Global Single-Photon Emission Computed Tomography (SPECT) Market to Grow by Over $620 Million at 6% CAGR During 2020-2024 | Technavio

Retrieved on: 
Monday, November 30, 2020
Other Manufacturing, Manufacturing, Neuroimaging, Medicine, Clinical medicine, Radiobiology, Medical imaging, Branches of biology, Emission computed tomography, Tomography, Single-photon emission computed tomography, Single-photon, CT scan, Advanced Cyclotron Systems

The single-photon emission computed tomography (SPECT) market is poised to grow by USD 620.21 million during 2020-2024, progressing at a CAGR of over 6% during the forecast period.

Key Points: 
  • The single-photon emission computed tomography (SPECT) market is poised to grow by USD 620.21 million during 2020-2024, progressing at a CAGR of over 6% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201130005583/en/
    Technavio has announced its latest market research report titled Global Single-Photon Emission Computed Tomography (SPECT) Market 2020-2024 (Graphic; Business Wire)
    Worried about the impact of COVID-19 on your Business?
  • The report on the single-photon emission computed tomography (SPECT) market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The single-photon emission computed tomography (SPECT) market analysis includes the product, application, and geography landscape.

Global Single Photon Emission Computed Tomography (SPECT) Market Research Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 27, 2020
Medical devices, Health, Medicine, Neuroimaging, Clinical medicine, Medical physics, Radiobiology, Medical imaging, Branches of biology, Emission computed tomography, Tomography, CT scan, Single-photon emission computed tomography, Single-photon

Amid the COVID-19 crisis, the global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.

Key Points: 
  • Amid the COVID-19 crisis, the global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.
  • Cardiology, one of the segments analyzed in the report, is projected to record a 5.6% CAGR and reach US$762.7 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $390.2 Million, While China is Forecast to Grow at 4.5% CAGR
    The Single Photon Emission Computed Tomography (SPECT) market in the U.S. is estimated at US$390.2 Million in the year 2020.
  • The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

Retrieved on: 
Thursday, October 8, 2020
Medicine, Medicinal radiochemistry, Clinical medicine, Physical sciences, Medical physics, Medical imaging, Neuroimaging, Radiology, Single-photon emission computed tomography, Nuclear medicine, Emission computed tomography, Positron emission tomography

Presently, a variety of diagnostic and therapeutic techniques are based on the use of such substances, commonly referred to as radiopharmaceuticals.

Key Points: 
  • Presently, a variety of diagnostic and therapeutic techniques are based on the use of such substances, commonly referred to as radiopharmaceuticals.
  • Typically, diagnostic tests, involving radiopharmaceuticals, are performed using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET).
  • Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines.
  • The 'Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030' report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals.

Nuclear Imaging Devices And Equipment Global Market Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 9, 2019
Medical devices, Health, Medicine, Medical physics, Branches of biology, Neuroimaging, Nuclear medicine, Clinical medicine, Image processing, Tomography, Emission computed tomography, Medical imaging, PET-CT, PET-MRI

The "Nuclear Imaging Devices And Equipment Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Imaging Devices And Equipment Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • The nuclear imaging devices and equipment market consists of sales of nuclear imaging devices and related services.
  • The nuclear imaging devices and equipment market is being restrained by strict regulations by the Nuclear Regulatory Commission (NRC) medical use.
  • Companies in the nuclear imaging devices and equipment market are using hybrid imaging technologies such as positron emission tomography/computed tomography (PET/CT), single-photon emission computed tomography/computed tomography (SPECT/CT), and positron emission tomography/magnetic resonance imaging (PET/MRI) for nuclear medical imaging.

$3.3 Billion Nuclear Imaging Devices Market is Restrained by Strict Regulations Says a TBRC Report

Retrieved on: 
Thursday, September 12, 2019
Medicine, Medical imaging, Medical physics, Branches of biology, Neuroimaging, Applied sciences, Nuclear medicine, Medicinal radiochemistry, Emission computed tomography, Tomography, PET-CT, Positron Corporation

LONDON, Sept. 12, 2019 /PRNewswire/ -- The nuclear imaging devices and equipment market is being restrained by strict regulations by the Nuclear Regulatory Commission (NRC) medical use.

Key Points: 
  • LONDON, Sept. 12, 2019 /PRNewswire/ -- The nuclear imaging devices and equipment market is being restrained by strict regulations by the Nuclear Regulatory Commission (NRC) medical use.
  • The Nuclear Regulatory Commission (NRC), USA, regulates the manufacture and use of radioactive materials in nuclear imaging devices, as well as radiation therapy and research.
  • The global nuclear imaging devices and equipment market was valued at about $3.3 billion in 2018 and is expected to grow to $3.76 billion at an annual growth rate of 3.3% through 2022.
  • Request A Free Sample Of The Nuclear Imaging Devices And Equipment Market Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2399&type=smp
    Companies in the nuclear imaging devices and equipment market are using hybrid imaging technologies such as positron emission tomography/computed tomography (PET/CT), single-photon emission computed tomography/computed tomography (SPECT/CT), and positron emission tomography/magnetic resonance imaging (PET/MRI) for nuclear medical imaging.